Terms: = Prostate cancer AND H3F3B, H3_3A, 3021, ENSG00000132475, P84243, H3_3B, MGC87783, MGC87782, H3F3
5 results:
1. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
2. Genetic polymorphisms in CDH1 and Exo1 genes elevate the prostate cancer risk in Bangladeshi population.
Imtiaz H; Afroz S; Hossain MA; Bellah SF; Rahman MM; Kadir MS; Sultana R; Mazid MA; Rahman MM
Tumour Biol; 2019 Mar; 41(3):1010428319830837. PubMed ID: 30880589
[TBL] [Abstract] [Full Text] [Related]
3. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance.
Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
Eur J Pharm Sci; 2019 Apr; 131():177-194. PubMed ID: 30776468
[TBL] [Abstract] [Full Text] [Related]
4. BRCA1 and p53 regulate critical prostate cancer pathways.
De Luca P; Moiola CP; Zalazar F; Gardner K; Vazquez ES; De Siervi A
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):233-8. PubMed ID: 23670255
[TBL] [Abstract] [Full Text] [Related]
5. BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer.
De Luca P; Vazquez ES; Moiola CP; Zalazar F; Cotignola J; Gueron G; Gardner K; De Siervi A
Mol Cancer Res; 2011 Aug; 9(8):1078-90. PubMed ID: 21700680
[TBL] [Abstract] [Full Text] [Related]
